PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

BACKGROUND. PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expressio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Yarchoan, Mark, Albacker, Lee A., Hopkins, Alexander C., Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T., Zaidi, Neeha, Azad, Nilofer S., Laheru, Daniel A., Frampton, Garrett M., Jaffee, Elizabeth M.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2019
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482991/
https://ncbi.nlm.nih.gov/pubmed/30895946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.126908
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars